Market Overview

Why Calliditas Therapeutics Stock Trading Higher Today


Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.

Calliditas Therapeutics operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.

Calliditas Therapeutics shares were trading up 20.05% at $23.95 at the time of publication Tuesday. The stock has a 52-week high of $24.97 and a 52-week low of $19.


Latest Ratings for CALT

Jun 2020StifelInitiates Coverage OnBuy
Jun 2020JefferiesInitiates Coverage OnBuy

View More Analyst Ratings for CALT
View the Latest Analyst Ratings


Related Articles (CALT)

View Comments and Join the Discussion!

Posted-In: why it's movingAnalyst Color News Price Target Initiation Analyst Ratings Movers Trading Ideas

Latest Ratings

TYGB of A SecuritiesUpgrades
ZIONB of A SecuritiesMaintains39.0
RFB of A SecuritiesMaintains13.0
PNCB of A SecuritiesMaintains123.0
HBANB of A SecuritiesMaintains11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at